July 8, 2026 · Blood · DOI: 10.1182/blood.2026034193

The CYB5R3 T117S Missense Variant is Associated with Attenuated Riociguat Efficacy in Sickle Cell Disease

Listen to this summary

The authors investigate the impact of the CYB5R3 T117S missense variant on the efficacy of riociguat, a soluble guanylyl cyclase stimulator, in patients with sickle cell disease. They find that this variant is associated with reduced effectiveness of riociguat, suggesting that CYB5R3 plays a crucial role in modulating nitric oxide signaling and vascular function in this condition.

Katherine C Wood, Seyed Mehdi Nouraie, Mark T Gladwin, Enrico M Novelli, Victor R Gordeuk, Claudia R Morris, Caterina P Minniti, Kenneth I Ataga, Payal Chandarana Desai, Kaleab Z Abebe, Adam C Straub

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play